Abstract
Cancer genomes contain many aberrant gene fusions—a few that drive disease and many more that are nonspecific passengers. We developed an algorithm (the concept signature or 'ConSig' score) that nominates biologically important fusions from high-throughput data by assessing their association with 'molecular concepts' characteristic of cancer genes, including molecular interactions, pathways and functional annotations. Copy number data supported candidate fusions and suggested a breakpoint principle for intragenic copy number aberrations in fusion partners. By analyzing lung cancer transcriptome sequencing and genomic data, we identified a novel R3HDM2-NFE2 fusion in the H1792 cell line. Lung tissue microarrays revealed 2 of 76 lung cancer patients with genomic rearrangement at the NFE2 locus, suggesting recurrence. Knockdown of NFE2 decreased proliferation and invasion of H1792 cells. Together, these results present a systematic analysis of gene fusions in cancer and describe key characteristics that assist in new fusion discovery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Mitelman, F., Johansson, B. & Mertens, F. The impact of translocations and gene fusions on cancer causation. Nat. Rev. Cancer 7, 233–245 (2007).
Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005).
Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).
Kumar-Sinha, C., Tomlins, S.A. & Chinnaiyan, A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497–511 (2008).
Vastrik, I. et al. Reactome: a knowledge base of biologic pathways and processes. Genome Biol. 8, R39 (2007).
Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y. & Hattori, M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 32, D277–280 (2004).
Prasad, T.S. et al. Human Protein Reference Database–2009 update. Nucleic Acids Res. 37, D767–72 (2009).
Hu, Z. et al. VisANT 3.0: new modules for pathway visualization, editing, prediction and construction. Nucleic Acids Res. 35, W625–632 (2007).
Chen, C. et al. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr. Relat. Cancer 14, 513–529 (2007).
Chen, G.J., Weylie, B., Hu, C., Zhu, J. & Forough, R. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J. Cell. Biochem. 101, 1492–1504 (2007).
Vantler, M. et al. PI3-kinase/Akt-dependent antiapoptotic signaling by the PDGF alpha receptor is negatively regulated by Src family kinases. FEBS Lett. 580, 6769–6776 (2006).
Walz, C., Cross, N.C., Van Etten, R.A. & Reiter, A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia 22, 1320–1334 (2008).
Fuhrer, D.K. & Yang, Y.C. Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Biochem. Biophys. Res. Commun. 224, 289–296 (1996).
Kharas, M.G. et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J. Clin. Invest. 118, 3038–3050 (2008).
Mullighan, C.G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
Mullighan, C.G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758–764 (2007).
Drexler, H.G. . The Leukemia-Lymphoma Cell Line Factsbook (Academic Press, San Diego, 2000).
Mitelman, F., Mertens, F. & Johansson, B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15 Spec No 417–474 (1997).
Maher, C.A. et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc. Natl. Acad. Sci. USA 106, 12353–12358 (2009).
Bashir, A., Volik, S., Collins, C., Bafna, V. & Raphael, B.J. Evaluation of paired-end sequencing strategies for detection of genome rearrangements in cancer. PLoS Comput. Biol. 4, e1000051 (2008).
Kent, W.J. BLAT–the BLAST-like alignment tool. Genome Res. 12, 656–664 (2002).
Wishart, D.S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668–D672 (2006).
Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004).
Weir, B.A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893–898 (2007).
Richard, W. Overall experiment characteristics. National Cancer Institute 〈https://array.nci.nih.gov/caarray/project/woost-00041〉 (2009).
Roth, R.B. et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 7, 67–80 (2006).
Rhodes, D.R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166–180 (2007).
Rubin, M.A. et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 64, 3814–3822 (2004).
Garraway, L.A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005).
Cao, Q. et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27, 7274–7284 (2008).
Acknowledgements
We thank F. Mitelman for offering the fusion genes list from the Mitelman database; T.W. Glover for the important comments for improving the manuscript; J. Granger for help with editing the manuscript; S. Qin for useful discussions about biostatistics; NCIBI colleagues L. Ke and A. Ade for helping in the implementation of tools and technologies; C. Yang for the guidance in drug informatics; Z. Hu from Boston University for help with network visualization. This work was supported by the National Institutes of Health (NIH; U54 DA021519) and a National Institutes of Health Cancer Biology Training Grant (CA009676-18 to J.R.P). J.R.P. is a Fellow of the University of Michigan Medical Scientist Training Program. A.M.C. is supported by NIH early detection network U01 CA111275, DOD W81XWH-09-2-0014, the Doris Duke Foundation and the American Cancer Society.
Author information
Authors and Affiliations
Contributions
X-S.W., G.S.O. and A.M.C. designed the study. X-S.W., J.R.P. and M.A.S. performed bioinformatics analyses. X-S.W., J.R.P., G.C., Q.C., S.M.D., R.P., X.C. and S.V. performed experimental studies. B.H. and N.P. performed FISH analysis. D.G.T., T.J.G. and D.G.B. coordinated the clinical and pathology components. X-S.W., J.R.P., G.S.O. and A.M.C. wrote the manuscript.
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Results (PDF 1812 kb)
Rights and permissions
About this article
Cite this article
Wang, XS., Prensner, J., Chen, G. et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol 27, 1005–1011 (2009). https://doi.org/10.1038/nbt.1584
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1584
This article is cited by
-
Genomic and immunogenomic analysis of three prognostic signature genes in LUAD
BMC Bioinformatics (2023)
-
ROP: dumpster diving in RNA-sequencing to find the source of 1 trillion reads across diverse adult human tissues
Genome Biology (2018)
-
Insights into molecular therapy of glioma: current challenges and next generation blueprint
Acta Pharmacologica Sinica (2017)
-
Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer
BMC Systems Biology (2014)
-
PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling
Oncogene (2014)